Spain releases framework for cannabis-based medicine prescribing
Spain's Ministry of Health this week unveiled a draft Royal Decree for public consultation outlining proposed regulations for the prescription of cannabis-based medicines, Cannabis Business reported.
The news comes after years of negotiations and increased legal production of medical cannabis, as previously reported.
In June 2022, the Health Committee of Spain's House of Representatives initially approved a draft subcommittee report outlining a series of recommendations for regulating cannabis-derived medicines for therapeutic purposes.
Following delays in the process due to the change of government in 2023, Health Minister Monica García appeared in parliament for the first time in early January and said the process to launch a medical cannabis framework would be restarted.
In line with the health committee's recommendations, the latest framework allows for the following:
Prescription of cannabis medicines in the form of “master formulas”. Specialist doctors prescribe medical cannabis for conditions such as spasticity in multiple sclerosis (MS), severe and intractable epilepsy, chemotherapy-induced nausea and vomiting, and intractable chronic pain.
Medical cannabis flower is not included in the law.
Related article: One Spanish politician calls cannabis 'the most dangerous drug', another defends cannabis, pushes for stricter alcohol regulations
Get Benzinga's exclusive analysis and top cannabis industry and market news delivered to your inbox every day, free of charge. Subscribe to our newsletter here. If you're serious about your business, you can't afford to miss it.
This Cannabis Company Achieves Record Growth in Germany: Revenue Increases by 50%, Here's Why
Meanwhile, IM Cannabis Corp. IMCC IMCC on Wednesday reported preliminary sales results in Germany for the third quarter of 2024 by its German-operating subsidiary, Adjupharm GmbH. Results were significantly better than expected, with medical cannabis operations in Israel and Germany reporting a 50% increase in revenue compared to the previous quarter.
IMC CEO Oren Schuster said this was due to the partial legalization of cannabis in Germany this spring.
“Since April 1, one of our key goals has been to ensure our supply chain is strong enough to meet the increased demand,” Shuster said, adding that “this interim The 50% growth is in part proof that this goal has been achieved. We are excited about our third quarter performance. This not only exceeded our own goals, but highlighted the dedication and hard work of our entire team. ”
Read next:
Market news and data powered by Benzinga API
© 2024 Benzinga.com. Benzinga does not provide investment advice. Unauthorized reproduction is prohibited.
